IndustryCompany release

Mentari Therapeutics completes InMed merger and $490M private placements; begins Nasdaq trading as MTRI

🇺🇸 InMed Pharmaceuticals Inc. (INM) · Mon 09 Nov 2026

On November 9, 2026, Mentari Therapeutics closed its merger with InMed Pharmaceuticals and began trading on the Nasdaq Capital Market under the ticker MTRI. Just before closing, it completed private placements worth about $490 million in gross proceeds, which it says funds operations into 2029. The company is developing PACAP-targeting migraine-prevention antibodies: MT-001 is in Phase 1 with initial data expected mid-2027, and a regulatory filing for the bispecific MT-002 is planned for Q1 2027.

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →